Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Long-Term Investments (2016 - 2021)

Historic Long-Term Investments for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $513.7 million.

  • Neurocrine Biosciences' Long-Term Investments rose 18318.63% to $513.7 million in Q3 2021 from the same period last year, while for Sep 2021 it was $513.7 million, marking a year-over-year increase of 18318.63%. This contributed to the annual value of $227.1 million for FY2020, which is 2422.42% down from last year.
  • Neurocrine Biosciences' Long-Term Investments amounted to $513.7 million in Q3 2021, which was up 18318.63% from $337.8 million recorded in Q2 2021.
  • Neurocrine Biosciences' 5-year Long-Term Investments high stood at $513.7 million for Q3 2021, and its period low was $37.7 million during Q1 2017.
  • Over the past 5 years, Neurocrine Biosciences' median Long-Term Investments value was $216.0 million (recorded in 2018), while the average stood at $231.4 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' Long-Term Investments soared by 65711.24% in 2017, and later plummeted by 4125.5% in 2019.
  • Neurocrine Biosciences' Long-Term Investments (Quarter) stood at $247.4 million in 2017, then fell by 12.67% to $216.0 million in 2018, then skyrocketed by 38.73% to $299.7 million in 2019, then decreased by 24.22% to $227.1 million in 2020, then soared by 126.2% to $513.7 million in 2021.
  • Its Long-Term Investments stands at $513.7 million for Q3 2021, versus $337.8 million for Q2 2021 and $249.6 million for Q1 2021.